Melissa Toyos, Bausch & Lomb Inc (F), Carl Zeiss AG (F), Eyevance Pharmaceuticals (C), Iridex Corporation (F), Kala Pharmaceuticals Inc (F), Lumenis Ltd (F), Magellan Health (F), Mallinckrodt Pharmaceuticals (F), MiXto Laser (F), Ocular Technologies (F), Oculos Clinical Research (F), Opternative (F), RevitaLid Inc. (F), Shire plc (F), Sun Pharmaceutical Industries Ltd (F), Verana Health (F);
Damien Goldberg, Aerie Pharmaceuticals Inc (C), Allergan plc (C), Bausch Health Companies Inc (F), Carl Zeiss AG (F), Cloudbreak Therapeutics LLC (F), Glaukos Corporation (F), Johnson & Johnson Vision Care Inc (F), Kala Pharmaceuticals Inc (F), Ocular Science (F), Ocular Therapeutix Inc (F), Sun Pharmaceutical Industries Ltd (F), TearSolutions Inc (F);
Joseph Tauber, Sun Pharmaceutical Industries Ltd (F), Sun Pharmaceutical Industries Ltd (C);
Rajan Malhotra, Abbott Laboratories (F), Alcon (F), Allergan plc (F), Bausch & Lomb Inc (F), BioD LLC (F), InSite Vision Inc (F), Katena Products Inc (F), NicOx S.A. (F), OASIS Medical Inc (F), Shire plc (F), TearScience Inc (F);
Charles Darby, SPARC Ltd (C);
Abayomi Ogundele, Sun Pharmaceutical Industries Ltd (E);
Jodi Luchs, Alcon (F), Allergan plc (F), Bausch & Lomb Inc (F), CXLO (F), Insightful Solutions (F), Shire plc (F), Sun Pharmaceutical Industries Ltd (F), TearLab Corporation (F)